// App-Quantinova.ai

BSH19‐PO‐099 : Efficacy of Mogamulizumab by Prior Systemic Therapy in Patients With Previously Treated Cutaneous T‐Cell Lymphoma: Post Hoc Analysis From the Phase 3 MAVORIC Study

Researchers

Presenter

  • J. Scarisbrick

Principal Investigators

  • P.L. Zinzani

  • S. Horwitz

  • Y.H. Kim

  • A.J. Moskowitz

  • P. Porcu

  • M. Leoni

  • K. Dwyer

  • W. Sun

  • E. Nikonova

  • M. Bagot

Medical Centers

  • University of Birmingham, Birmingham, United Kingdom

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Stanford University Hospital, Stanford, CA

  • Thomas Jefferson University, Philadelphia, PA

  • Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ

  • Kyowa Kirin, Inc., Bedminster, New Jersey, United States

  • Hopital Saint-Louis, AP-HP, Universite Paris , Paris, France

Locations

  • United Kingdom

  • Italy

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mycosis fungoides

  • T-cell lymphoma

  • Lymphomas

Biomarkers

  • C-C Motif Chemokine Receptor 4

Drug/Treatment

  • Interferon alpha

  • Mogamulizumab

  • Methotrexate

  • Bexarotene

  • Romidepsin

  • Vorinostat

  • Interferon

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01728805

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved